September 2, 2025 - The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public warning regarding the circulation of a falsified Oxytocin injection identified as Gold Vision Oxytocin 10IU. The product, which bears a fake registration number A4-9566, was flagged during a risk-based sampling survey conducted by NAFDAC officers.
According to the agency, the injection is purportedly manufactured by Anhui Hongye Pharmaceutical Co., Ltd. in China and marketed locally by Gold Vision Medicals, based in Enugu. However, the product is not listed in NAFDAC’s official database of registered medicines, confirming its status as unregistered and falsified.
Further investigations revealed that three additional products—A-tocin Injection, Extocin Injection, and Claxitodin Injection—also carry the same falsified registration number and were reportedly manufactured by the same company. These findings emerged from the agency’s 2023 RBPMS sampling exercise.
NAFDAC has expressed serious concern over the health risks associated with the use of such counterfeit injections. Oxytocin is a critical medication used to induce uterine contractions during childbirth and to prevent postpartum haemorrhage. The agency warned that falsified versions may contain incorrect dosages, harmful contaminants, or no active ingredients at all—posing life-threatening risks to mothers and newborns.
“Poor-quality oxytocin may delay or fail to stop bleeding after childbirth,” the agency cautioned, “which increases the likelihood of emergency interventions such as blood transfusions or surgery.”
Healthcare professionals and consumers have been urged to remain vigilant and report any suspicious or substandard medicines to the nearest NAFDAC office. The agency reiterated its commitment to safeguarding public health and cracking down on the growing trend of unregistered drugs in Nigeria’s open market.
This latest warning follows previous alerts issued by NAFDAC, including the discovery of counterfeit batches of Postinor-2, an emergency contraceptive pill. The agency confirmed that two falsified versions of the product had been found in circulation, both posing serious health risks to users.
As NAFDAC intensifies its surveillance and enforcement efforts, the public is reminded to verify the authenticity of medical products and to rely only on registered and approved sources.
0 Comments